EF1α-GFP-H1-gRNA Two Vector Cas9 SmartNuclease™ gRNA Expression Lentivector
- Conduct genome editing and engineering in difficult-to-transfect cell lines
- Drive gRNA expression from the H1 promoter
- Assess transduction efficiency with the GFP marker
- Perform in vivo engineering of model organisms
- Supports synthetic biology applications, gene- and cell-based therapy development, and genome-wide functional screening
Products
| Catalog Number | Description | Size | Price | Quantity | Add to Cart | |||
|---|---|---|---|---|---|---|---|---|
| CASLV501PA-G | gRNA expression vector for the Two Vector EF1α-GFP-H1-gRNA linearized SmartNuclease Lentivector Plasmid | 10 Reactions | $643 |
|
||||
Overview
Overview
Genome editing in transfection-resistant cells
Efficiently deliver gRNA using our Cas9 SmartNuclease™ Lentivector System. Great for when you want to create stable Cas9 editing cell lines and/or would like to edit the genome of a cell line that is resistant to transfection by plasmids, the EF1α-GFP-H1-gRNA Two Vector Cas9 SmartNuclease gRNA Expression Lentivector works with any of our Cas9 SmartNuclease Lentivectors.
- Conduct genome editing and engineering in difficult-to-transfect cell lines
- Drive gRNA expression from the H1 promoter
- Assess transduction efficiency with the GFP marker
- Perform in vivo engineering of model organisms
- Supports synthetic biology applications, gene- and cell-based therapy development, and genome-wide functional screening
Why an HR targeting vector is a recommended
Even though gene knock-outs can result from DSBs caused by Cas9 alone, SBI recommends the use of HR targeting vectors (also called HR donor vectors) for more efficient and precise mutation. HR donors can supply elements for positive or negative selection ensuring easier identification of successful mutation events. In addition, HR donors can include up to 6-8 kb of open reading frame for gene knock-ins or tagging, and, when small mutations are included in either 5’ or 3’ homology arms, can make specific, targeted gene edits.
Not sure whether you need a CRISPR/Cas9 plasmid, purified protein, or mRNA?
Use this table to choose the CRISPR/Cas9 product that’s right for you:
For This Application | In these types of cells | Use These Products |
|---|---|---|
MODIFYING ORGANISMS
| Embryos—to create transgenic animals | Injectable Cas9 mRNA & gRNA Synthesis Kits Cas9 Protein EGFP-labeled Cas9 Protein |
| Animals models—in vivo genome editing | AAV-Cas9 Vectors Cas9 Protein EGFP-labeled Cas9 Protein |
|
MODIFYING CELL LINES
| Cells that are transfectable | Cas9 Plasmids Cas9 Protein EGFP-labeled Cas9 Protein |
Difficult-to-transfect cell lines:
| AAV-Cas9 Vectors Lenti Cas9 Systems |
|
SCREENING
| All cell types requiring stable Cas9 overexpression | Lenti Cas9 Systems AAVS1 Safe Harbor Site Cas9 Gene Knock-in System Cas9 Protein EGFP-labeled Cas9 Protein |
PRE-CLINICAL APPLICATIONS
| All cell types and applications | Cas9 Nickase, available in all delivery formats Cas9 Protein EGFP-labeled Cas9 Protein |
| SIMULTANEOUS ENGINEERING OF MULTIPLE MUTATIONS | All cell types and applications | Multiplex gRNA cloning kit, compatible with all Cas9 delivery options |
References
How It Works
How It Works
Genome engineering with CRISPR/Cas9
For general guidance on using CRISPR/Cas9 technology for genome engineering, take a look at our CRISPR/Cas9 tutorials as well as the following application notes:
CRISPR/Cas9 Gene Knock-Out Application Note (PDF) »
CRISPR/Cas9 Gene Editing Application Note (PDF) »
CRISPR/Cas9 Gene Tagging Application Note (PDF) »
CRISPR/Cas9 Basics
Through careful selection of the target sequence and design of a donor plasmid for homologous recombination, you can achieve efficient and highly targeted genomic modification with CRISPR/Cas9.
The system
Cas9 protein—uses guide RNA (gRNA) to direct site-specific, double-strand DNA cleavage adjacent to a protospacer adapter motif (PAM) in the target DNA.
gRNA—RNA sequence that guides Cas9 to cleave a homologous region in the target genome. Efficient cleavage only where the gRNA homology is adjacent to a PAM.
PAM—protospacer adapter motif, NGG, is a target DNA sequence that spCas9 will cut upstream from if directed to by the gRNA.
The workflow at-a-glance
DESIGN: Select gRNA and HR donor plasmids. Choice of gRNA site and design of donor plasmid determines whether the homologous recombination event results in a knock-out, knock-in, edit, or tagging.
CONSTRUCT: Clone gRNA into all-in-one Cas9 vector. Clone 5’ and 3’ homology arms into HR donor plasmid. If creating a knock-in, clone desired gene into HR donor.
CO-TRANSFECT or CO-INJECT: Introduce Cas9, gRNA, and HR Donors into the target cells using co-transfection for plasmids, co-transduction for lentivirus, or co-injection for mRNAs.
SELECT/SCREEN: Select or screen for mutants and verify.
VALIDATE: Genotype or sequence putative mutants to verify single or biallelic conversion.
Supporting Data
Supporting Data
See Two Vector Cas9 SmartNuclease Lentivectors in action
MSCV-driven Cas9 and CMV-driven Two Vector Cas9 SmartNuclease Lentivectors efficiently deliver Cas9 to transduced cells for efficient genome editing.
Two-Vector Cas9-Lentiviruses efficiently knockout stable RFP reporter gene
Figure 1. Two Vector Cas9 Lentiviruses efficiently knockout stable RFP reporter gene. METHODS: Phase and fluorescent images of modified HEK293T cells stably expressing RFP and GFP (top panels), which have been co-infected (MOI = 3) with the MSCV-Cas9-T2A-Puro Two Vector Cas9 SmartNuclease Lentivector (Cat.# CASLV125VA-1) and a gRNA virus expressing a guide RNA targeting RFP (EF1α-Blasticidin-H1-RFP gRNA, Cat.# CASLV500PA-B; bottom panels). Images of cells were taken 11 days after placing the cells under selection, and show ablation of RFP expression in target cells infected with both the Cas9-expressing Lentivector and gRNA-expressing Lentivector (bottom panels).
Transduce Cancer Cell Lines with Cas9-Lentivirus
Figure 2. Transduce Cancer Cell Lines with Cas9-Lentivirus. METHODS: (Top panels) Phase microscopy image of MCF-7 breast cancer cells infected with pseudoviral particles of CMV-hspCas9-T2A-Puro (Cat #CASLV100VA-1) and selected with Puromycin (1 µg/ml) for 10 days in culture, show distinct colony formation. (Bottom panels) Immunofluorescence staining of Cas9 protein expression in MCF-7 cell lines stably transduced with the CMV-hspCas9-T2A-Puro Two Vector Cas9 SmartNuclease Lentivector (Cat #CASLV100VA-1), show punctuate nuclear and perinuclear staining indicative of strong Cas9 protein expression in the nucleus.
FAQs
Resources
Citations
Related Products
Products
| Catalog Number | Description | Size | Price | Quantity | Add to Cart | |||
|---|---|---|---|---|---|---|---|---|
| CASLV501PA-G | gRNA expression vector for the Two Vector EF1α-GFP-H1-gRNA linearized SmartNuclease Lentivector Plasmid | 10 Reactions | $643 |
|
||||
Overview
Overview
Genome editing in transfection-resistant cells
Efficiently deliver gRNA using our Cas9 SmartNuclease™ Lentivector System. Great for when you want to create stable Cas9 editing cell lines and/or would like to edit the genome of a cell line that is resistant to transfection by plasmids, the EF1α-GFP-H1-gRNA Two Vector Cas9 SmartNuclease gRNA Expression Lentivector works with any of our Cas9 SmartNuclease Lentivectors.
- Conduct genome editing and engineering in difficult-to-transfect cell lines
- Drive gRNA expression from the H1 promoter
- Assess transduction efficiency with the GFP marker
- Perform in vivo engineering of model organisms
- Supports synthetic biology applications, gene- and cell-based therapy development, and genome-wide functional screening
Why an HR targeting vector is a recommended
Even though gene knock-outs can result from DSBs caused by Cas9 alone, SBI recommends the use of HR targeting vectors (also called HR donor vectors) for more efficient and precise mutation. HR donors can supply elements for positive or negative selection ensuring easier identification of successful mutation events. In addition, HR donors can include up to 6-8 kb of open reading frame for gene knock-ins or tagging, and, when small mutations are included in either 5’ or 3’ homology arms, can make specific, targeted gene edits.
Not sure whether you need a CRISPR/Cas9 plasmid, purified protein, or mRNA?
Use this table to choose the CRISPR/Cas9 product that’s right for you:
For This Application | In these types of cells | Use These Products |
|---|---|---|
MODIFYING ORGANISMS
| Embryos—to create transgenic animals | Injectable Cas9 mRNA & gRNA Synthesis Kits Cas9 Protein EGFP-labeled Cas9 Protein |
| Animals models—in vivo genome editing | AAV-Cas9 Vectors Cas9 Protein EGFP-labeled Cas9 Protein |
|
MODIFYING CELL LINES
| Cells that are transfectable | Cas9 Plasmids Cas9 Protein EGFP-labeled Cas9 Protein |
Difficult-to-transfect cell lines:
| AAV-Cas9 Vectors Lenti Cas9 Systems |
|
SCREENING
| All cell types requiring stable Cas9 overexpression | Lenti Cas9 Systems AAVS1 Safe Harbor Site Cas9 Gene Knock-in System Cas9 Protein EGFP-labeled Cas9 Protein |
PRE-CLINICAL APPLICATIONS
| All cell types and applications | Cas9 Nickase, available in all delivery formats Cas9 Protein EGFP-labeled Cas9 Protein |
| SIMULTANEOUS ENGINEERING OF MULTIPLE MUTATIONS | All cell types and applications | Multiplex gRNA cloning kit, compatible with all Cas9 delivery options |
References
How It Works
How It Works
Genome engineering with CRISPR/Cas9
For general guidance on using CRISPR/Cas9 technology for genome engineering, take a look at our CRISPR/Cas9 tutorials as well as the following application notes:
CRISPR/Cas9 Gene Knock-Out Application Note (PDF) »
CRISPR/Cas9 Gene Editing Application Note (PDF) »
CRISPR/Cas9 Gene Tagging Application Note (PDF) »
CRISPR/Cas9 Basics
Through careful selection of the target sequence and design of a donor plasmid for homologous recombination, you can achieve efficient and highly targeted genomic modification with CRISPR/Cas9.
The system
Cas9 protein—uses guide RNA (gRNA) to direct site-specific, double-strand DNA cleavage adjacent to a protospacer adapter motif (PAM) in the target DNA.
gRNA—RNA sequence that guides Cas9 to cleave a homologous region in the target genome. Efficient cleavage only where the gRNA homology is adjacent to a PAM.
PAM—protospacer adapter motif, NGG, is a target DNA sequence that spCas9 will cut upstream from if directed to by the gRNA.
The workflow at-a-glance
DESIGN: Select gRNA and HR donor plasmids. Choice of gRNA site and design of donor plasmid determines whether the homologous recombination event results in a knock-out, knock-in, edit, or tagging.
CONSTRUCT: Clone gRNA into all-in-one Cas9 vector. Clone 5’ and 3’ homology arms into HR donor plasmid. If creating a knock-in, clone desired gene into HR donor.
CO-TRANSFECT or CO-INJECT: Introduce Cas9, gRNA, and HR Donors into the target cells using co-transfection for plasmids, co-transduction for lentivirus, or co-injection for mRNAs.
SELECT/SCREEN: Select or screen for mutants and verify.
VALIDATE: Genotype or sequence putative mutants to verify single or biallelic conversion.
Supporting Data
Supporting Data
See Two Vector Cas9 SmartNuclease Lentivectors in action
MSCV-driven Cas9 and CMV-driven Two Vector Cas9 SmartNuclease Lentivectors efficiently deliver Cas9 to transduced cells for efficient genome editing.
Two-Vector Cas9-Lentiviruses efficiently knockout stable RFP reporter gene
Figure 1. Two Vector Cas9 Lentiviruses efficiently knockout stable RFP reporter gene. METHODS: Phase and fluorescent images of modified HEK293T cells stably expressing RFP and GFP (top panels), which have been co-infected (MOI = 3) with the MSCV-Cas9-T2A-Puro Two Vector Cas9 SmartNuclease Lentivector (Cat.# CASLV125VA-1) and a gRNA virus expressing a guide RNA targeting RFP (EF1α-Blasticidin-H1-RFP gRNA, Cat.# CASLV500PA-B; bottom panels). Images of cells were taken 11 days after placing the cells under selection, and show ablation of RFP expression in target cells infected with both the Cas9-expressing Lentivector and gRNA-expressing Lentivector (bottom panels).
Transduce Cancer Cell Lines with Cas9-Lentivirus
Figure 2. Transduce Cancer Cell Lines with Cas9-Lentivirus. METHODS: (Top panels) Phase microscopy image of MCF-7 breast cancer cells infected with pseudoviral particles of CMV-hspCas9-T2A-Puro (Cat #CASLV100VA-1) and selected with Puromycin (1 µg/ml) for 10 days in culture, show distinct colony formation. (Bottom panels) Immunofluorescence staining of Cas9 protein expression in MCF-7 cell lines stably transduced with the CMV-hspCas9-T2A-Puro Two Vector Cas9 SmartNuclease Lentivector (Cat #CASLV100VA-1), show punctuate nuclear and perinuclear staining indicative of strong Cas9 protein expression in the nucleus.